Rinvoq coverage guide: formulary, prior authorization, JAK safety requirements, and patient assistance

Rinvoq (upadacitinib, AbbVie) is a preferential JAK1 inhibitor approved for nine immune-mediated inflammatory conditions. Following the class-wide boxed warning issued by the FDA in 2022 after the ORAL Surveillance trial with tofacitinib, Rinvoq carries limitations that require TNF blocker failure before use in most indications. This creates a distinct access pathway compared with biologics like Skyrizi or Stelara, where TNF blocker failure is a payer preference but not an FDA label restriction.

This guide is for access teams, prior authorization coordinators, and prescribers navigating Rinvoq coverage across payer types and indications.

Short answer

FDA-approved indications and dosing

Rheumatoid arthritis (approved August 2019)

• Adults with moderately-to-severely active RA who have had an inadequate response or intolerance to one or more TNF blockers
• Dosing: 15 mg once daily

Psoriatic arthritis (approved June 2020)

• Adults with active PsA who have had an inadequate response or intolerance to one or more TNF blockers
• Pediatric patients 2 years and older with active PsA (Rinvoq LQ)
• Dosing: 15 mg once daily

Atopic dermatitis (approved January 2022)

• Adults and pediatric patients 12 years and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable
• Dosing: 15 mg or 30 mg once daily (initiate at 15 mg; may increase to 30 mg if adequate response not achieved)

Ulcerative colitis (approved April 2022)

• Adults with moderately-to-severely active UC who have had an inadequate response or intolerance to one or more TNF blockers
• Induction: 45 mg once daily for 8 weeks
• Maintenance: 15 mg once daily (may increase to 30 mg based on response)

Crohn's disease (approved June 2023)

• Adults with moderately-to-severely active CD who have had an inadequate response or intolerance to one or more TNF blockers
• Induction: 45 mg once daily for 12 weeks
• Maintenance: 15 mg once daily (may increase to 30 mg based on response)

Ankylosing spondylitis (approved April 2024)

• Adults with active AS who have had an inadequate response or intolerance to one or more TNF blockers
• Dosing: 15 mg once daily

Non-radiographic axial spondyloarthritis (approved April 2024)

• Adults with active nr-axSpA with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy
• Dosing: 15 mg once daily

Polyarticular juvenile idiopathic arthritis (approved April 2024)

• Patients 2 years and older with active pJIA who have had an inadequate response or intolerance to one or more TNF blockers
• Dosing: Rinvoq LQ oral solution, weight-based

Giant cell arteritis (approved April 2025)

• Adults with GCA
• Dosing: 15 mg once daily (no TNF blocker prerequisite, but patient must have tried or be taking a glucocorticoid unless contraindicated)

Pending indication (submitted April 2026)

• AbbVie submitted an FDA application for severe alopecia areata in adults and adolescents, based on the Phase 3 UP-AA program where upadacitinib met the primary endpoint of SALT score ≤20 at week 24.

Boxed warning and safety considerations

The FDA issued a class-wide boxed warning for all JAK inhibitors (tofacitinib, baricitinib, upadacitinib) in 2022, covering:

• Serious infections: Including tuberculosis, invasive fungal infections, bacterial, viral, and opportunistic infections
• Mortality: Increased all-cause mortality
• Malignancies: Including lymphoma
• Major adverse cardiovascular events (MACE): Myocardial infarction and stroke
• Thrombosis: Deep venous thrombosis, pulmonary embolism, and arterial thrombosis

The boxed warning applies to all JAK inhibitors regardless of individual drug selectivity. This creates two access barriers:

1. FDA label limitation: Rinvoq is labeled for use after TNF blocker failure in most indications (except AD and GCA), which is more restrictive than the label for biologics like Skyrizi or Stelara.
2. Payer safety screening: Many payers require documentation that the patient is not a current or past smoker, does not have cardiovascular risk factors, and understands the risk-benefit profile.

Coverage by payer type

Commercial insurance

Rinvoq is covered by most major commercial plans as a specialty-tier medication. Prior authorization is universally required.

Typical PA criteria for rheumatoid arthritis:

1. Diagnosis of moderately-to-severely active RA
2. Documented inadequate response, intolerance, or contraindication to one or more TNF blockers (≥3-month trial at appropriate dose)
3. Not currently on another JAK inhibitor, biologic DMARD, or potent immunosuppressant (azathioprine, cyclosporine, mycophenolate)
4. Prescribed by or in consultation with a rheumatologist
5. TB and hepatitis B screening completed

Typical PA criteria for atopic dermatitis:

1. Diagnosis of refractory, moderate-to-severe AD in patient age 12+
2. Failure of a multi-step topical therapy sequence commonly required by payers:
   • High-potency topical corticosteroid (e.g., clobetasol, betamethasone)
   • Topical calcineurin inhibitor (e.g., tacrolimus ointment)
   • Topical JAK inhibitor (e.g., Opzelura/ruxolitinib) where applicable
   • Topical PDE-4 inhibitor (e.g., Eucrisa/crisaborole) where applicable
3. Failure, contraindication, or intolerance to other systemic therapies including biologics (e.g., Dupixent/dupilumab, Ebglyss/lebrikizumab)
4. Not combined with other systemic targeted immunomodulators

Typical PA criteria for Crohn's disease and ulcerative colitis:

1. Confirmed diagnosis of moderately-to-severely active CD or UC
2. Inadequate response or intolerance to one or more TNF blockers (updated November 2025 at some payers to also allow failure of an approved systemic therapy besides a TNF inhibitor)
3. Failure of conventional therapies (corticosteroids, immunomodulators)
4. Not combined with other JAK inhibitors or biologic therapies for the same indication

Specialty pharmacy requirements

Rinvoq is designated as a specialty medication by most major payers and must be dispensed through a contracted specialty pharmacy. This means:

• Retail pharmacies typically cannot fill Rinvoq prescriptions
• Patients receive medication through mail-order specialty pharmacies designated by the plan
• AbbVie's Rinvoq Complete program can help coordinate specialty pharmacy enrollment
• If the dose is being escalated or changed (e.g., from 15 mg to 30 mg for AD or UC), a separate PA may be required for the new strength

Quantity limits

Prescriber specialty requirements

Most payers require Rinvoq to be prescribed by or in consultation with a physician who specializes in the condition being treated:

PA response timing

Standard PA decisions are typically returned within 30 days. Urgent or expedited requests are generally processed within 72 hours. Submit through the payer's electronic portal for fastest processing.

Medicare Part D

Rinvoq is covered under Medicare Part D. The IRA out-of-pocket cap is $2,100 for 2026.

Key 2026 Medicare provisions:

• $2,100 annual out-of-pocket cap for all Part D drugs
• Medicare Prescription Payment Plan (MPPP) allows monthly installment payments
• Low-Income Subsidy (LIS) patients pay $12.65 or less per fill
• Medicare Advantage plans may apply additional utilization management

Medicaid

State Medicaid programs cover Rinvoq with prior authorization. PA criteria mirror commercial requirements with possible additional state-specific documentation. Cost is typically $8/month or less depending on the state plan.

Prior authorization process

Required documentation

Reauthorization requirements

• Authorization duration: typically 12 months for most indications; 6 months initial for atopic dermatitis
• Documentation of positive clinical response (reduced disease activity, improved signs/symptoms)
• Continued compliance with safety monitoring
• Not combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants

Common denial reasons and solutions

Cost and patient assistance

Manufacturer savings programs

Important notes on the savings card:

• Not valid for Medicare, Medicaid, TRICARE, VA, or other government-funded insurance
• Patients enrolled in copay maximizer or optimizer programs may have a reduced annual maximum benefit
• The maximum annual benefit is subject to change without notice
• Copay assistance may be discontinued if AbbVie determines the patient is subject to a copay maximizer program

Cost by insurance type

What changed in 2026

• Updated IBD indication statements (October 2025): The FDA approved updated indication statements for Rinvoq in Crohn's disease and ulcerative colitis, allowing the prerequisite therapy to include an approved systemic therapy besides a TNF inhibitor when TNF blockers are clinically inadvisable.
• Cigna PA criteria update (November 2025): Updated CD/UC criteria to reflect the allowance for systemic therapy besides a TNF inhibitor prior to Rinvoq.
• Giant cell arteritis approval (April 2025): The newest indication, with the unique feature of not requiring TNF blocker failure—only a glucocorticoid trial.
• Alopecia areata submission (April 2026): AbbVie submitted a new indication application for severe alopecia areata based on the Phase 3 UP-AA program. If approved, this would be the tenth indication.
• Medicare Part D $2,100 out-of-pocket cap: Effective January 2026 under the IRA.
• Ongoing safety monitoring: AbbVie continues to accumulate long-term safety data across 27 clinical trials and over 15,000 patients, which is relevant for any potential future label differentiation from the class-wide boxed warning.

What to monitor

• Alopecia areata FDA decision: If approved, this would expand Rinvoq into dermatology beyond atopic dermatitis and could shift payer coverage criteria.
• JAK inhibitor label differentiation: Monitor whether long-term safety data supports any FDA labeling changes that distinguish Rinvoq from less selective JAK inhibitors.
• Payer step therapy evolution: As biologics like Skyrizi and Stelara face biosimilar competition and pricing shifts, some payers may reconsider step therapy sequences that currently require TNF blocker failure before JAK inhibitor use.
• Competitive landscape: Monitor new oral small molecules and next-generation JAK inhibitors that could affect formulary positioning.
• IRA expanded negotiation: Monitor whether Rinvoq is selected for future Medicare price negotiation rounds, which could affect Part D pricing.

Sources

• FDA, Rinvoq prescribing information (revised April 2025): https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211675s025lbl.pdf
• AbbVie, Rinvoq HCP coverage and access: https://www.rinvoqhcp.com/access
• AbbVie, FDA approves updated IBD indication statement (October 2025): https://news.abbvie.com/2025-10-13-U-S-Food-and-Drug-Administration-FDA-Approves-Updated-Indication-Statement-for-RINVOQ-R-upadacitinib-for-the-Treatment-of-Inflammatory-Bowel-Disease
• AbbVie, alopecia areata FDA submission (April 2026): https://news.abbvie.com/2026-04-28-AbbVie-Submits-Application-to-FDA-for-Upadacitinib-RINVOQ-R-for-Adults-and-Adolescents-with-Severe-Alopecia-Areata
• UnitedHealthcare, Rinvoq PA criteria (effective February 2026): https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Med-Nec-Rinvoq-Rinvoq_LQ.pdf
• Cigna, Rinvoq PA policy (reviewed February 2026): https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_444_coveragepositioncriteria_inflammatory_conditions_rinvoq_pa.pdf
• Mass General Brigham Health Plan, Rinvoq PA criteria (effective April 2025): https://resources.massgeneralbrighamhealthplan.org/pharmacy/PharmacyPolicies/Commercial/Rinvoq_PA_ComExch_Rx_4.1.2025.pdf
• FDA, JAK inhibitor safety communication: https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk
• AbbVie, Rinvoq savings card terms: https://www.rinvoq.com/resources/save-on-rinvoq-costs
• AbbVie, myAbbVie Assist patient assistance: https://www.abbvie.com/patients/patient-support/patient-assistance.html
• PrescriberPoint, Rinvoq coverage and dosing: https://prescriberpoint.com/therapies/rinvoq-2966aec